Key facts
- MindWalk's preclinical dengue data supports HYFT computational predictions.
- Immunogens designed on HYFT's predicted target elicited cross-reactive antibodies.
- Antibodies were effective against all four dengue serotypes.
- Results were reproduced across two independent campaigns.
MindWalk has presented preclinical data for its dengue vaccine candidate that aligns with predictions made by the HYFT® computational platform. The immunogens, designed based on HYFT's predicted target, successfully induced cross-reactive antibodies. These antibodies demonstrated efficacy against antigens from all four known dengue serotypes. The findings were further validated through reproduction in two independent experimental campaigns, suggesting robustness in both the computational prediction and the resulting immunogen design.